Donate to Remove ads

Got a credit card? use our Credit Card & Finance Calculators

Thanks to Anonymous,johnhemming,Anonymous,Rhyd6,dredd0, for Donating to support the site

AstraZeneca PLC (AZN)

Share latest information on individual companies and hot news discussions. LSE Main Market companies only
Forum rules
No penny shares or promotional posts
idpickering
Lemon Half
Posts: 5557
Joined: November 4th, 2016, 5:04 pm
Has thanked: 882 times
Been thanked: 1978 times

Re: AstraZeneca PLC (AZN)

#290015

Postby idpickering » March 12th, 2020, 7:05 am

Update on Phase III GY004 trial for cediranib

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced high-level results from the Phase III GY004 trial, led by NRG Oncology and sponsored by the US National Cancer Institute (NCI), that examined primarily the efficacy and safety of the potential new medicine cediranib added to Lynparza (olaparib) versus platinum-based chemotherapy in patients with platinum-sensitive relapsed ovarian cancer. Ovarian cancer is the eighth most common cause of death from cancer in women worldwide.

The trial did not meet the primary endpoint in the intent-to-treat (ITT) population of a statistically significant improvement in progression-free survival (PFS) with cediranib added to Lynparza versus platinum-based chemotherapy. Cediranib is an oral vascular endothelial growth factor receptor (VEGFR) inhibitor, which blocks the growth of blood vessels supporting tumour growth.


https://www.investegate.co.uk/astrazene ... 00048940F/

idpickering
Lemon Half
Posts: 5557
Joined: November 4th, 2016, 5:04 pm
Has thanked: 882 times
Been thanked: 1978 times

Re: AstraZeneca PLC (AZN)

#302813

Postby idpickering » April 24th, 2020, 7:40 am

Lynparza shows overall survival in prostate cancer

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced further positive results from the Phase III PROfound trial of Lynparza (olaparib) in men with metastatic castration-resistant prostate cancer (mCRPC) who have a homologous recombination repair gene mutation (HRRm) and have progressed on prior treatment with new hormonal agent (NHA) treatments (e.g. enzalutamide and abiraterone).

Results from the trial showed a statistically significant and clinically meaningful improvement in the key secondary endpoint of overall survival (OS) with Lynparza versus enzalutamide or abiraterone in men with mCRPC selected for BRCA1/2 or ATM gene mutations, a subpopulation of HRR gene mutations.

https://www.investegate.co.uk/astrazene ... 00037689K/

ADrunkenMarcus
Lemon Slice
Posts: 789
Joined: November 5th, 2016, 11:16 am
Has thanked: 201 times
Been thanked: 205 times

Re: AstraZeneca PLC (AZN)

#302828

Postby ADrunkenMarcus » April 24th, 2020, 9:09 am

AstraZeneca has been a welcome part of my portfolio, up 42% in the last year or so including dividends.

idpickering
Lemon Half
Posts: 5557
Joined: November 4th, 2016, 5:04 pm
Has thanked: 882 times
Been thanked: 1978 times

Re: AstraZeneca PLC (AZN)

#302857

Postby idpickering » April 24th, 2020, 10:33 am

ADrunkenMarcus wrote:AstraZeneca has been a welcome part of my portfolio, up 42% in the last year or so including dividends.


Likewise regarding being a welcome part of my portfolio. They sit alongside GSK in the sector for me in my HYP, with AZN making up 4.1% in capital value terms, of my 28 share HYP. My average buy price on AZN is 4468p, so I'm showing a 82% gain in capital value, ignoring dividends received

Ian.

idpickering
Lemon Half
Posts: 5557
Joined: November 4th, 2016, 5:04 pm
Has thanked: 882 times
Been thanked: 1978 times

Re: AstraZeneca PLC (AZN)

#304005

Postby idpickering » April 29th, 2020, 7:20 am

First-quarter 2020 results

https://www.astrazeneca.com/content/dam ... cement.pdf

Also on HYP Practical.

idpickering
Lemon Half
Posts: 5557
Joined: November 4th, 2016, 5:04 pm
Has thanked: 882 times
Been thanked: 1978 times

Re: AstraZeneca PLC (AZN)

#306143

Postby idpickering » May 6th, 2020, 4:09 pm

Farxiga approved by FDA for heart failure (HFrEF).

AstraZeneca's Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death and hospitalisation for heart failure in adults with heart failure (NYHA class II-IV) with reduced ejection fraction (HFrEF) with and without type-2 diabetes (T2D).


https://www.investegate.co.uk/astrazene ... 00080846M/

ADrunkenMarcus
Lemon Slice
Posts: 789
Joined: November 5th, 2016, 11:16 am
Has thanked: 201 times
Been thanked: 205 times

Re: AstraZeneca PLC (AZN)

#306162

Postby ADrunkenMarcus » May 6th, 2020, 5:22 pm

AZN is headed to £90 at this rate.

Bouleversee
Lemon Quarter
Posts: 2686
Joined: November 8th, 2016, 5:01 pm
Has thanked: 572 times
Been thanked: 397 times

Re: AstraZeneca PLC (AZN)

#306170

Postby Bouleversee » May 6th, 2020, 5:34 pm

A golden beacon in a sea of red.

idpickering
Lemon Half
Posts: 5557
Joined: November 4th, 2016, 5:04 pm
Has thanked: 882 times
Been thanked: 1978 times

Re: AstraZeneca PLC (AZN)

#306174

Postby idpickering » May 6th, 2020, 5:43 pm

I just wish I'd bought more of these in the past. I was always swayed towards buying more GSK as it had a higher yield than AZN on the occasions I was considering buying either. Not to worry. I'm happy to hold both, and have no intention of selling either of them any time soon.

Ian.

ADrunkenMarcus
Lemon Slice
Posts: 789
Joined: November 5th, 2016, 11:16 am
Has thanked: 201 times
Been thanked: 205 times

Re: AstraZeneca PLC (AZN)

#306198

Postby ADrunkenMarcus » May 6th, 2020, 7:00 pm

Astra was my best performer within the last year, contributing in no small part to keeping my portfolio's loss on a total return basis to 3.3%.

Best wishes

Mark.

Bouleversee
Lemon Quarter
Posts: 2686
Joined: November 8th, 2016, 5:01 pm
Has thanked: 572 times
Been thanked: 397 times

Re: AstraZeneca PLC (AZN)

#306203

Postby Bouleversee » May 6th, 2020, 7:26 pm

Mine, too. Others had been better at one point but that has all changed and none of those high flyers are now paying dividends either.

ADrunkenMarcus
Lemon Slice
Posts: 789
Joined: November 5th, 2016, 11:16 am
Has thanked: 201 times
Been thanked: 205 times

Re: AstraZeneca PLC (AZN)

#306214

Postby ADrunkenMarcus » May 6th, 2020, 8:20 pm

Bouleversee wrote:Mine, too. Others had been better at one point but that has all changed and none of those high flyers are now paying dividends either.


AZN's dividend is looking more secure than in a long while IMHO.

It cost them $3,592 million in 2019.

Free cashflow is forecast at $4,022 million for 2020, $5,919 for 2021 and $7,172 for 2022, so if these forecasts are right then the dividend (at present levels) will be covered roughly twice over by free cashflow by 2022.

Also, by 2022 net borrowing as a proportion of free cash flow should be down to under 1.4 if forecasts are right, driven by a substantial increase in free cash flow and an absolute reduction in debt on the balance sheet.

Best wishes

Mark.

idpickering
Lemon Half
Posts: 5557
Joined: November 4th, 2016, 5:04 pm
Has thanked: 882 times
Been thanked: 1978 times

Re: AstraZeneca PLC (AZN)

#310485

Postby idpickering » May 21st, 2020, 7:21 am

AstraZeneca advances response to COVID-19 outbreak

AstraZeneca is advancing its ongoing response to address the unprecedented challenges of COVID-19, collaborating with a number of countries and multilateral organisations to make the University of Oxford's vaccine widely accessible around the world in an equitable manner.

The Company has concluded the first agreements for at least 400 million doses and has secured total manufacturing capacity for one billion doses so far and will begin first deliveries in September 2020. AstraZeneca aims to conclude further agreements supported by several parallel supply chains, which will expand capacity further over the next months to ensure the delivery of a globally accessible vaccine.

AstraZeneca today received support of more than $1bn from the US Biomedical Advanced Research and Development Authority (BARDA) for the development, production and delivery of the vaccine, starting in the fall. The development programme includes a Phase III clinical trial with 30,000 participants and a paediatric trial.

https://www.investegate.co.uk/astrazene ... 00105972N/

Bouleversee
Lemon Quarter
Posts: 2686
Joined: November 8th, 2016, 5:01 pm
Has thanked: 572 times
Been thanked: 397 times

Re: AstraZeneca PLC (AZN)

#310565

Postby Bouleversee » May 21st, 2020, 10:47 am

idpickering wrote:AstraZeneca advances response to COVID-19 outbreak

AstraZeneca is advancing its ongoing response to address the unprecedented challenges of COVID-19, collaborating with a number of countries and multilateral organisations to make the University of Oxford's vaccine widely accessible around the world in an equitable manner.

The Company has concluded the first agreements for at least 400 million doses and has secured total manufacturing capacity for one billion doses so far and will begin first deliveries in September 2020. AstraZeneca aims to conclude further agreements supported by several parallel supply chains, which will expand capacity further over the next months to ensure the delivery of a globally accessible vaccine.

AstraZeneca today received support of more than $1bn from the US Biomedical Advanced Research and Development Authority (BARDA) for the development, production and delivery of the vaccine, starting in the fall. The development programme includes a Phase III clinical trial with 30,000 participants and a paediatric trial.

https://www.investegate.co.uk/astrazene ... 00105972N/


It all sounds marvellous but if you read on, the picture is not quite so rosy, e.g.:

"A Phase I/II clinical trial of AZD1222 began last month to assess safety, immunogenicity and efficacy in over 1,000 healthy volunteers aged 18 to 55 years across several trial centres in southern England. Data from the trial is expected shortly which, if positive, would lead to late-stage trials in a number of countries. AstraZeneca recognises that the vaccine may not work but is committed to progressing the clinical program with speed and scaling up manufacturing at risk."

Full marks for getting the arrangements in place, though at governments' expense it would seem. I am a little confused about whether they are going to manufacture and distribute all these vaccine doses before they know whether it works or not but it sounds as though that is the plan.

As regards the financial implications for AZN, they are saying their guidance has not changed (I haven't checked what that was as yet) but I seem to remember their saying their work in this connection was being done on a not for profit basis. The s.p. has continued risen quite a lot since March (down around 2% today but so is the FTSE), unlike that of most companies, but with a p/e ratio of 105.50 is probably up with, if not ahead of, events. What do others think after reading the full RNS? I am still debating whether to bed and ISA my non-ISA holding. In most cases when I have done this, e.g. Marston's and Greggs, the s.p. has subsequently plummeted.


Return to “Company Share news (LSE Main Market)”

Who is online

Users browsing this forum: JuanDB and 2 guests